KUALA LUMPUR: Apex Healthcare Bhd is not expected to be negatively impacted by the proposed medicine price control measure, says Affin Hwang Capital research.
The price control measure is mainly focused on lowering the prices of single-source drugs to ensure their affordability, although this will unlikely affect the pharmaceutical group as it does not produce any single-source drugs.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!